Acumen Pharmaceuticals, Inc. filings document a clinical-stage biopharmaceutical issuer focused on Alzheimer’s disease programs targeting toxic soluble amyloid beta oligomers. Its Form 8-K reports include operating and financial results, business highlights, Regulation FD presentation updates, clinical and nonclinical program disclosures, and material agreements related to Enhanced Brain Delivery development.
Proxy materials describe annual meeting voting matters, board elections, auditor ratification, and equity incentive plan approvals. The filing record also discloses ABOS common stock registered on the Nasdaq Global Select Market, emerging growth company status, governance changes, capital-structure matters, and clinical and regulatory disclosure categories tied to drug development.
Acumen Pharmaceuticals, Inc. (ABOS) reported that initial topline results from its Phase 2 ALTITUDE-AD trial of sabirnetug did not meet the primary endpoint of change from baseline in cognitive and functional decline at 18 months versus placebo at either 35 mg/kg or 50 mg/kg. Key secondary endpoints, including CDR-SB, also did not achieve statistical significance, and neither treatment arm showed a meaningful difference from placebo.
Sabirnetug was generally well tolerated; ARIA-E was observed in approximately 10% of treated participants. PET SUVr analysis showed statistically significant amyloid plaque reduction at both doses at weeks 36 and 76. Acumen plans to cease sabirnetug development, including the ALTITUDE-AD open-label extension, and evaluate strategic options, including its Enhanced Brain Delivery program. It also plans cash-conservation measures and expects additional fluid biomarker and imaging data in the coming weeks, which it does not expect to change the efficacy conclusions.
Acumen Pharmaceuticals, Inc. (ABOS) may offer and sell up to $500,000,000 in aggregate offering price of common stock, preferred stock, debt securities and warrants. Each sale requires a prospectus supplement. Acumen currently intends to use net proceeds for its planned Phase 3 sabirnetug trial, working capital, capital expenditures and general corporate purposes.
Acumen plans to announce top-line results from its Phase 2 ALTITUDE-AD trial in November 2026. Designed for 542 participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease, the trial uses iADRS at 18 months as its primary outcome; active doses are 35 mg/kg and 50 mg/kg intravenously every four weeks.
In June 2026, Acumen exercised its exclusive option to license and develop two EBD development candidates under its collaboration with JCR Pharmaceuticals Co. Ltd.; the $9.25 million option payment was paid in July 2026. JCR is eligible for up to $555.0 million in development and sales milestones, plus single-digit percentage royalties on sales. Acumen expects to cease emerging growth company status on December 31, 2026.
Acumen Pharmaceuticals, Inc. reported a net loss of $78.8 million for the nine months ended September 30, 2026, compared with $96.2 million a year earlier. Research and development expense was $65.4 million, down from $84.4 million, primarily reflecting lower ALTITUDE-AD manufacturing and contract research costs; higher EBD® license and preclinical costs partly offset the decrease. Operating cash used was $68.9 million versus $96.4 million.
At September 30, cash and marketable securities totaled $78.6 million. Management expects that balance to fund operations into early 2027 and concluded substantial doubt exists about the company’s ability to continue as a going concern. Acumen has no approved products or product-sales revenue. Its Phase 2 ALTITUDE-AD trial is designed for 542 participants, and top-line results are planned for November 2026. In June 2026, Acumen exercised its option to license two EBD® candidates from JCR, paying $9.25 million; JCR may receive up to $555.0 million in development and sales milestones plus single-digit royalties. A private placement of 10,833,331 shares at $3.30 per share closed in March 2026, generating approximately $35.7 million gross before approximately $0.3 million in offering costs.
Acumen Pharmaceuticals, Inc. (ABOS) reported third-quarter 2026 financial results and business updates. Cash, cash equivalents and marketable securities totaled $78.6 million as of September 30, 2026, compared with $110.2 million as of June 30, 2026; the company expects the balance to support current clinical and operational activities into early 2027. For the quarter, net loss was $25.369 million versus $26.451 million a year earlier, research and development expense was $21.113 million versus $21.968 million, and general and administrative expense was $4.700 million versus $4.545 million. For the nine months ended September 30, 2026, net loss was $78.824 million versus $96.197 million.
Acumen expects ALTITUDE-AD Phase 2 topline results in November 2026. The trial enrolled 542 participants with early Alzheimer’s disease and evaluates sabirnetug; expected results include the primary iADRS efficacy endpoint, secondary endpoints including CDR-SB, safety measures including ARIA rates, and biomarkers. Acumen is targeting a mid-2027 investigational new drug (IND) filing for a lead candidate in its Enhanced Brain Delivery program.
Acumen Pharmaceuticals, Inc. (ABOS) furnished an Investor Day presentation outlining its Alzheimer’s disease pipeline and development timelines. The company states its cash, cash equivalents and marketable securities are expected to be sufficient into early 2027.
The presentation highlights sabirnetug (ACU193), an IgG2 monoclonal antibody selectively targeting amyloid‑β oligomers, with the global Phase 2 ALTITUDE‑AD trial (542 patients, 80‑week treatment) using iADRS as the primary endpoint and topline results expected in late 2026. Phase 1 data described limited ARIA‑E incidence and biomarker improvements after three doses.
Acumen also describes an Enhanced Brain Delivery (EBD®) platform using transferrin‑receptor–mediated bispecific antibodies (ACU301, ACU401) designed for subcutaneous dosing and higher brain exposure, with an IND filing for a lead EBD candidate targeted for mid‑2027. The 8‑K states this information is being furnished under Regulation FD and not deemed filed.
Acumen Pharmaceuticals, Inc. is a clinical-stage biotech focused on Alzheimer’s disease, advancing its anti-amyloid-beta oligomer antibody sabirnetug in the Phase 2 ALTITUDE-AD trial, with top-line results planned for late 2026. The company also nominated two Enhanced Brain Delivery™ candidates, ACU301 and ACU401, under its JCR collaboration and exercised an option in June 2026, triggering a $9.25 million in‑process R&D payment.
For the six months ended June 30, 2026, Acumen reported a net loss of $53.5 million, improving from $69.7 million in 2025, as research and development expenses fell to $44.3 million from $62.4 million primarily due to lower manufacturing and CRO costs on ALTITUDE-AD. General and administrative expenses were stable at $9.4 million. Cash, cash equivalents and marketable securities totaled $110.2 million as of June 30, 2026, helped by a March 2026 private placement raising about $35.7 million gross.
The company carries an accumulated deficit of $499.9 million and continues to incur operating losses. Management states that current cash resources are expected to fund operations into early 2027 but may not cover at least 12 months beyond the financial statement issuance date, leading to a disclosed substantial doubt about its ability to continue as a going concern.
Acumen Pharmaceuticals, Inc. reported second quarter 2026 results and updated progress on its Alzheimer’s disease pipeline. For the quarter ended June 30, 2026, the company recorded a net loss of $32.7 million, improved from $41.0 million a year earlier, as research and development expenses declined to $27.8 million from $37.1 million, mainly from lower manufacturing, materials and CRO costs tied to the ALTITUDE-AD trial. General and administrative expenses were stable at $4.7 million.
Cash, cash equivalents and marketable securities totaled $110.2 million as of June 30, 2026, down from $128.4 million at March 31, 2026, and are expected to fund current clinical and operational activities into early 2027. The balance sheet showed total assets of $116.0 million, total liabilities of $58.7 million and stockholders’ equity of $57.3 million, with short-term debt of $19.7 million and long-term debt of $11.9 million. The company raised $35.4 million net from a private placement in the first half of 2026.
Operationally, Acumen highlighted its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in 542 participants with early Alzheimer’s disease, with topline results expected in late 2026, and continued development of its Enhanced Brain Delivery™ (EBD™) program, targeting an IND filing for a lead EBD candidate in mid-2027.
Acumen Pharmaceuticals director Derrell Porter reported a series of option exercises and matching share sales in Common Stock. On June 15–17, 2026, he exercised options for a total of 19,500 shares at $1.07 per share and sold 32,300 shares in open-market transactions at weighted average prices around $2.32 per share, with individual trades ranging from $2.305 to $2.345. Following these transactions, Porter directly holds 35,500 shares of Acumen Pharmaceuticals Common Stock. The options exercised had vested in full on the date of the 2026 annual stockholder meeting.
ABOS files a Rule 144 notice for the sale of 13,040 shares. The filing lists the method as a Stock Option Exercise dated 06/17/2026 with cash proceeds. It also reports prior dispositions of 12,800 shares on 06/16/2026 for $29,767.68 and 6,460 shares on 06/15/2026 for $15,148.70.